GO:0061099 negative regulation of protein tyrosine kinase activity: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061099 describes any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity, a central brake on intracellular phosphotyrosine signaling.
• Negative regulation is achieved by multiple mechanisms including inhibitory phosphorylation, SH2/SH3 domain autoinhibition, substrate degradation, and feedback phosphatases.
• Csk (C-terminal Src kinase) is a prototypical negative regulator that phosphorylates the inhibitory C-terminal tyrosine of Src-family kinases to suppress T-cell receptor signaling.
• TULA proteins and SOCS family members provide additional layers of negative control over Syk and cytokine receptor-associated tyrosine kinases.
• Loss of negative regulation of tyrosine kinases is linked to cancer, immune dysregulation, and developmental brain disorders.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in disease.
Description
Protein tyrosine kinases (PTKs) are enzymes that transfer the gamma-phosphate of ATP to tyrosine residues on substrate proteins, thereby initiating or amplifying intracellular signaling cascades. Because unchecked PTK activity can drive uncontrolled proliferation, inflammation, and developmental defects, cells have evolved dedicated processes that decrease the rate, frequency, or extent of PTK activity, collectively annotated as GO:0061099 negative regulation of protein tyrosine kinase activity. This GO term captures a biological process rather than a single molecular event, encompassing inhibitory phosphorylation, domain-mediated autoinhibition, substrate degradation, and feedback inhibition by phosphatases and suppressor proteins. The importance of this process is underscored by the fact that the first characterized oncogenes were constitutively active tyrosine kinases, and restoring negative regulation is a long-standing therapeutic goal. For example, the Src protein tyrosine kinase is kept inactive by intramolecular interactions involving its SH2 and SH3 domains and by phosphorylation of a C-terminal inhibitory tyrosine. Similarly, Csk-mediated phosphorylation of Src-family kinases provides a critical negative checkpoint in T-cell receptor signaling. In the brain, regulated degradation of activated PTK substrates contributes to proper neuronal development, illustrating that negative regulation can occur at the level of substrate stability. For researchers, GO:0061099 provides a conceptual and experimental framework to identify and validate negative regulators of PTK signaling. Understanding which proteins enforce this brake, how they are themselves regulated, and how their loss contributes to disease is essential for target discovery in oncology, immunology, and neurobiology. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to describe the mechanisms, key genes, disease links, and CRISPR-based research methods relevant to GO:0061099.
negative regulation of protein tyrosine kinase activity At A Glance
| GO ID | GO:0061099 |
|---|---|
| GO term | negative regulation of protein tyrosine kinase activity |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency, or extent of protein tyrosine kinase activity, thereby attenuating phosphotyrosine signaling |
| Definition source | QuickGO definition: Any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity |
| Representative regulators | Csk, TULA proteins, SOCS proteins, SH2/SH3 domain-containing inhibitors |
| Representative targets | Src-family kinases, Syk, Abl, cytokine receptor-associated kinases |
| Disease relevance | Cancer, immune dysregulation, developmental brain disorders |
What Is GO:0061099?
GO:0061099 negative regulation of protein tyrosine kinase activity is defined by QuickGO as any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity. In practical terms, it refers to cellular mechanisms that dampen or shut off the enzymatic function of tyrosine kinases, thereby reducing tyrosine phosphorylation of downstream substrates and attenuating the signaling pathways they control. This process can act directly on the kinase (for example, through inhibitory phosphorylation or autoinhibitory domain interactions) or indirectly (for example, by degrading the kinase or its substrates, or by activating counteracting phosphatases).
Why Is negative regulation of protein tyrosine kinase activity Important in Cell Biology?
Negative regulation of protein tyrosine kinase activity is a fundamental homeostatic mechanism that prevents excessive or inappropriate signaling through phosphotyrosine pathways. Because tyrosine kinases control cell growth, differentiation, immune responses, and neuronal development, their activity must be tightly constrained; failure of this negative regulation is a common route to oncogenesis and immune pathology. Studying GO:0061099 therefore informs both basic signal transduction biology and the development of therapeutic strategies that aim to restore inhibitory control over hyperactive kinases.
• Prevents uncontrolled proliferation by restraining oncogenic tyrosine kinases such as Src and Abl.
• Sets the threshold for T-cell receptor signaling through Csk-mediated inhibitory phosphorylation.
• Limits cytokine signaling via SOCS-mediated negative feedback on receptor-associated kinases.
• Controls Syk activity in hematopoietic cells through TULA protein interactions.
• Contributes to brain development by regulating degradation of activated PTK substrates.
• Provides mechanistic rationale for targeting negative regulators in cancer therapy.
• Helps explain immune dysregulation when negative checkpoints are lost.
• Guides CRISPR model design to test causality of candidate negative regulators.
• Informs biomarker discovery for kinase-driven diseases.
• Supports synthetic lethality approaches combining kinase inhibitors with loss of negative regulators.
What Happens During negative regulation of protein tyrosine kinase activity?
Inhibitory phosphorylation of the kinase
In simple terms: A dedicated enzyme adds a phosphate tag to the kinase that switches it off.
The best-characterized mechanism of negative regulation is phosphorylation of a conserved C-terminal tyrosine residue in Src-family kinases by Csk (C-terminal Src kinase), which stabilizes an autoinhibited conformation and suppresses downstream signaling. This inhibitory phosphorylation is a direct biochemical means of decreasing PTK activity and is essential for setting the activation threshold of T-cell receptor signaling. The SH2 domain of Src-family kinases binds the inhibitory phosphotyrosine, locking the kinase in a closed, inactive state.
Domain-mediated autoinhibition
In simple terms: Parts of the kinase fold back and block its own active site.
Src-family kinases contain SH3 and SH2 domains that engage intramolecular ligands to maintain an inactive conformation. Disruption of these intramolecular interactions, for example by high-affinity ligands or mutations, releases autoinhibition and increases kinase activity. This intrinsic negative regulation is a first layer of control that can be reinforced by extrinsic factors such as Csk.
Substrate degradation as a negative feedback mechanism
In simple terms: The cell destroys the activated target protein to stop the signal.
During brain development, activated protein tyrosine kinase substrates can be targeted for degradation, providing a negative feedback mechanism that terminates signaling. This mode of negative regulation acts downstream of the kinase and reduces the effective amplitude of the pathway without directly inhibiting the kinase catalytic domain. It illustrates that GO:0061099 encompasses processes that decrease PTK activity indirectly by removing its substrates.
Suppressor proteins and feedback inhibition
In simple terms: Dedicated brake proteins bind and shut down the kinase or its signaling partners.
TULA proteins regulate the activity of the protein tyrosine kinase Syk, acting as negative regulators in hematopoietic signaling. SOCS family proteins provide negative feedback in cytokine signaling pathways by binding to receptor-associated kinases and targeting them for inhibition or degradation. These suppressor proteins add specificity and inducible control to the negative regulation of PTK activity.
Integration with phosphatase and kinase networks
In simple terms: Brakes and accelerators are balanced to keep signaling in a useful range.
Negative regulation of PTK activity operates in concert with protein tyrosine phosphatases that remove phosphotyrosine marks, and with positive feedback loops that can reactivate kinases. The net signaling output reflects the balance between kinase activity and the multiple negative regulatory mechanisms described above. Dysregulation of this balance, for example by loss of Csk or SOCS function, can shift cells toward constitutive activation of tyrosine kinase pathways.
Key Genes Involved in GO:0061099 negative regulation of protein tyrosine kinase activity
The following genes and proteins are established participants in or targets of negative regulation of protein tyrosine kinase activity (GO:0061099), based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSK | Phosphorylates inhibitory C-terminal tyrosine of Src-family kinases | Key negative regulator of T-cell receptor signaling; knockout models show hyperactive Src-family kinases |
| SRC | Prototypical tyrosine kinase subject to SH2/SH3 autoinhibition and Csk-mediated inhibition | Model for studying autoinhibition and negative regulation mechanisms |
| ABL1 | Tyrosine kinase whose deregulation affects cell death and proliferation | Target for understanding negative regulation in leukemia and cell death pathways |
| SYK | Tyrosine kinase regulated by TULA proteins in hematopoietic cells | Model for suppressor protein control of immune signaling |
| TULA (UBASH3A/UBASH3B) | Binds and negatively regulates Syk activity | Candidate negative regulators in immune and hematopoietic research |
| SOCS1 | Negative feedback regulator of cytokine receptor-associated kinases | Central to cytokine signaling restraint and immune homeostasis |
| SOCS3 | Negative feedback regulator of cytokine signaling | Important in inflammation and cytokine-driven disease models |
| PTPN6 (SHP-1) | Phosphatase that counteracts tyrosine kinase signaling | Contributes to negative regulation by removing phosphotyrosine marks |
| PTPN11 (SHP-2) | Phosphatase involved in modulating tyrosine kinase pathways | Relevant to signaling balance and disease when mutated |
| CBL | E3 ubiquitin ligase that targets activated tyrosine kinases for degradation | Links substrate degradation to negative regulation of PTK signaling |
| SH3 domain-containing adaptors | Mediate autoinhibitory interactions in Src-family kinases | Used to dissect domain-mediated negative regulation |
| SH2 domain-containing proteins | Bind inhibitory phosphotyrosine to lock kinases inactive | Tool for studying conformational control of kinase activity |
| MKK6 (MAP2K6) | Subject to negative feedback regulation by p38alpha MAPK | Illustrates feedback control principles relevant to kinase networks |
| p38alpha (MAPK14) | Mediates negative feedback regulation of MKK6 mRNA stability | Model for feedback inhibition in kinase cascades |
| JAK family kinases | Targets of SOCS-mediated negative regulation | Central to cytokine signaling and immune disease research |
| STAT proteins | Downstream effectors whose activation is limited by SOCS feedback | Readout of negative regulation in cytokine pathways |
| BCR-ABL1 | Constitutively active tyrosine kinase lacking normal negative regulation | Model for oncogenic kinase activation and therapeutic targeting |
How Is negative regulation of protein tyrosine kinase activity Regulated?
Negative regulation of protein tyrosine kinase activity is itself regulated at multiple levels. Csk activity and localization determine the extent of inhibitory phosphorylation of Src-family kinases. TULA proteins modulate Syk activity in a context-dependent manner. SOCS proteins are induced by cytokine signaling and provide negative feedback that limits the duration and intensity of JAK-STAT pathway activation. In addition, p38alpha MAPK can negatively regulate MKK6 mRNA stability, illustrating cross-talk between kinase cascades that indirectly influences tyrosine kinase signaling networks. These layers ensure that negative regulation is dynamic and responsive to cellular state.
negative regulation of protein tyrosine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSK | T-cell hyperactivation and autoimmunity | Csk knockout or point-mutation T cells |
| SRC | Oncogenic transformation and cancer | Src overexpression and autoinhibition mutant models |
| BCR-ABL1 | Chronic myeloid leukemia | Knock-in of BCR-ABL1 fusion in hematopoietic cells |
| SOCS1 | Inflammatory and autoimmune disease | SOCS1 knockout mice and cytokine challenge |
| SYK | Hematopoietic malignancies and immune disorders | Syk knock-in with TULA-binding mutations |
Cancer
Loss of negative regulation of protein tyrosine kinase activity is a hallmark of many cancers. Constitutively active Src and BCR-ABL1 escape normal inhibitory control, leading to uncontrolled proliferation and survival. Mutations or epigenetic silencing of negative regulators such as Csk or SOCS proteins can further amplify oncogenic tyrosine kinase signaling. Restoring negative regulation is therefore an attractive therapeutic strategy.
Immune dysregulation and autoimmunity
Csk-mediated inhibition of Src-family kinases is essential for setting the threshold of T-cell receptor signaling, and its disruption leads to aberrant immune activation. SOCS proteins restrain cytokine signaling, and their dysfunction is associated with inflammatory and autoimmune conditions. TULA-mediated regulation of Syk further highlights the importance of negative regulation in immune cell homeostasis.
Neurodevelopmental disorders
Regulated degradation of activated protein tyrosine kinase substrates during brain development is required for proper neuronal differentiation and circuit formation. Disruption of this negative regulatory mechanism can lead to developmental brain abnormalities. This underscores the importance of GO:0061099 beyond cancer and immunology.
From negative regulation of protein tyrosine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Csk increase Src-family kinase activity? | CSK knockout cell line |
| Does a specific C-terminal tyrosine mutation prevent inhibitory phosphorylation? | SRC point-mutation knock-in |
| Does TULA binding regulate Syk activity? | SYK knock-in with mutated TULA-binding site |
| Does SOCS1 feedback limit cytokine signaling? | SOCS1 overexpression and knockout models |
| Does substrate degradation control PTK signaling in neurons? | Tagged knock-in of PTK substrates in neuronal cells |
| Can negative regulators be identified genome-wide? | CRISPR library screening in kinase-driven cancer cells |
How to Study the negative regulation of protein tyrosine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphotyrosine Western blot | Overall tyrosine phosphorylation levels | Rapid assessment of PTK activity changes |
| Quantitative phosphoproteomics | Site-specific tyrosine phosphorylation | Global mapping of negative regulation effects |
| In vitro kinase assay | Catalytic activity of purified kinases | Testing inhibitory phosphorylation or domain mutations |
| Co-immunoprecipitation | Physical interaction between kinase and regulator | Validating Csk-Src or TULA-Syk complexes |
| CRISPR knockout screening | Gene requirement for signaling output | Discovery of novel negative regulators |
| RNA-seq | Transcriptional changes upon regulator loss | Identifying downstream pathways |
| Proximity labeling | Interactome of kinase or regulator | Mapping transient regulatory complexes |
| Live-cell FRET biosensors | Real-time kinase activity dynamics | Monitoring negative regulation kinetics |
Phosphotyrosine profiling by mass spectrometry
Quantitative phosphoproteomics can measure changes in tyrosine phosphorylation across the proteome upon manipulation of negative regulators, providing a global readout of GO:0061099 activity. This approach identifies direct and indirect substrates of tyrosine kinases and reveals pathway rewiring when negative regulation is lost.
Kinase activity assays
In vitro kinase assays using recombinant Src-family kinases or Syk can directly measure the effect of inhibitory phosphorylation, domain mutations, or suppressor proteins on catalytic activity. These assays provide biochemical evidence for negative regulation mechanisms.
Co-immunoprecipitation and proximity labeling
Protein-protein interaction methods can detect complexes between tyrosine kinases and their negative regulators, such as Csk-Src or TULA-Syk. Proximity labeling extends this to transient or low-affinity interactions in living cells.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain alters tyrosine kinase signaling output, uncovering novel negative regulators. These screens are particularly powerful when coupled with phospho-specific readouts or viability assays in kinase-driven cancer models.
How CRISPR Can Be Used to Study GO:0061099 negative regulation of protein tyrosine kinase activity
Knockout
CRISPR knockout of negative regulators such as CSK or SOCS1 allows researchers to observe the consequences of losing the brake on tyrosine kinase activity. These models are used to confirm that a candidate gene is required for restraining PTK signaling and to identify downstream transcriptional or phenotypic changes.
Point Mutation
Point mutations can be introduced into the inhibitory C-terminal tyrosine of Src-family kinases or into regulatory domains to test their role in negative regulation. Such models distinguish between catalytic activity and regulatory control, providing mechanistic insight into GO:0061099.
Knock-in
Knock-in of tagged or mutant versions of kinases and their regulators enables precise tracking of protein localization, stability, and interactions. For example, tagging endogenous Syk or its substrates can reveal how TULA binding or degradation controls signaling.
Overexpression
Overexpression of negative regulators such as SOCS proteins or TULA can suppress tyrosine kinase signaling and is used to test sufficiency of the negative regulation. Conversely, overexpression of constitutively active kinases can overwhelm negative regulation, modeling oncogenic states.
How EDITGENE Supports negative regulation of protein tyrosine kinase activity Research
Researchers studying negative regulation of protein tyrosine kinase activity-related genes often need to determine whether a candidate gene is causally involved in restraining kinase signaling or in disease progression. Rigorous causal inference requires precise genetic models that can isolate loss-of-function, gain-of-function, and regulatory mutations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of protein tyrosine kinase activity research.
Frequently Asked Questions About negative regulation of protein tyrosine kinase activity
What is GO:0061099 negative regulation of protein tyrosine kinase activity?
GO:0061099 is a Gene Ontology biological process term defined as any process that decreases the rate, frequency, or extent of protein tyrosine kinase activity.
What genes are involved in negative regulation of protein tyrosine kinase activity?
Key genes include CSK, SRC, SYK, TULA (UBASH3A/UBASH3B), SOCS1, SOCS3, and phosphatases such as PTPN6.
How does Csk negatively regulate Src-family kinases?
Csk phosphorylates the inhibitory C-terminal tyrosine of Src-family kinases, locking them in an inactive conformation and suppressing downstream signaling.
What is the role of SH2 and SH3 domains in negative regulation?
SH2 and SH3 domains mediate intramolecular interactions that maintain Src-family kinases in an autoinhibited state, contributing to negative regulation.
How do TULA proteins regulate Syk?
TULA proteins bind and negatively regulate the protein tyrosine kinase Syk, modulating hematopoietic signaling.
What is the link between negative regulation of tyrosine kinases and cancer?
Loss of negative regulation leads to constitutive activation of oncogenic kinases such as Src and BCR-ABL1, driving uncontrolled proliferation and survival.
Can CRISPR be used to study negative regulation of protein tyrosine kinases?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect negative regulatory mechanisms.
What methods measure negative regulation of tyrosine kinase activity?
Phosphotyrosine Western blotting, quantitative phosphoproteomics, in vitro kinase assays, and CRISPR screens are commonly used.
How does SOCS feedback regulate cytokine signaling?
SOCS proteins are induced by cytokines and provide negative feedback that limits JAK-STAT pathway activation.
Why is substrate degradation important for negative regulation?
Degradation of activated PTK substrates during brain development terminates signaling and contributes to proper neuronal differentiation.
Conclusion
GO:0061099 negative regulation of protein tyrosine kinase activity is a critical biological process that restrains phosphotyrosine signaling through inhibitory phosphorylation, autoinhibition, substrate degradation, and suppressor proteins. Its dysfunction is implicated in cancer, immune dysregulation, and neurodevelopmental disorders, making it a rich area for mechanistic and translational research. CRISPR-based models and phosphoproteomic methods provide powerful tools to dissect these mechanisms and identify new therapeutic targets.
References
- 1. Superti-Furga G. 1995. Regulation of the Src protein tyrosine kinase.. FEBS Lett 369(1):62-6 PMID: 7641886
- 2. Wang JY. 2000. Regulation of cell death by the Abl tyrosine kinase.. Oncogene 19(49):5643-50 PMID: 11114745
- 3. Chow LM et al.. 1993. Negative regulation of T-cell receptor signalling by tyrosine protein kinase p50csk.. Nature 365(6442):156-60 PMID: 8371758
- 4. Liu X et al.. 1994. Biochemistry of the Src protein-tyrosine kinase: regulation by SH2 and SH3 domains.. Recent Prog Horm Res 49:149-60 PMID: 7511826
- 5. Arnaud L et al.. 2003. Regulation of protein tyrosine kinase signaling by substrate degradation during brain development.. Mol Cell Biol 23(24):9293-302 PMID: 14645539
- 6. Agrawal R et al.. 2008. TULA proteins regulate activity of the protein tyrosine kinase Syk.. J Cell Biochem 104(3):953-64 PMID: 18189269
- 7. Ambrosino C et al.. 2003. Negative feedback regulation of MKK6 mRNA stability by p38alpha mitogen-activated protein kinase.. Mol Cell Biol 23(1):370-81 PMID: 12482988
- 8. Yasukawa H et al.. 2000. Negative regulation of cytokine signaling pathways.. Annu Rev Immunol 18:143-64 PMID: 10837055
